Zenagamtide compared with semaglutide for type 2 diabetes not controlled by current treatment
Compares zenagamtide with semaglutide in adults with type 2 diabetes on metformin or SGLT2i.
Plain-language title generated from the registry record
Registry title: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
Key facts
- Where
- Albany, Boston, Bristol, Canton, Charleston, City of Saint Peters, Flint, Greensboro, Gurnee, Hollywood, Houston, Jacksonville, Katy, Kingsport, La Jolla, La Mesa, Lancaster, Las Vegas, Los Angeles, Meridian, Miami, Miami Gardens, Miramar, Monroe, Mt. Dora, Nashua, Nashville, Northridge, Ocoee, Olney, Orlando, Palm Springs, Phoenix, Renton, Rockville, San Antonio, San Diego, Sandy City, Santa Ana, Shavano Park, Sioux Falls, Spartanburg, Spring Valley, Tampa, Topeka, Walnut Creek, Waterbury, Weslaco, West Seneca, Weston, and Wilmington, United StatesSee the 55 sites
- Phase
- Phase 3
Where in United States
- AMC Community EndocrinologyAlbany, United StatesContact: Novo NordiskNo longer taking part
- Brigham & Women's HospitalBoston, United StatesContact: Novo NordiskNo longer taking part
- Holston Medical Group PcBristol, United StatesContact: Novo NordiskNo longer taking part
- Diab & Endo Assoc of Stark CoCanton, United StatesContact: Novo NordiskNo longer taking part
- DelRicht Research at Newton Family MedicineCharleston, United StatesContact: Novo NordiskNo longer taking part
- StudyMetrix Research, LLCCity of Saint Peters, United StatesContact: Novo NordiskNo longer taking part
- Elite Clinical ResearchFlint, United StatesContact: Novo NordiskNo longer taking part
- PharmQuest Life Sciences LLCGreensboro, United StatesContact: Novo NordiskNo longer taking part
- Clinical Invest Special_GurneeGurnee, United StatesContact: Novo NordiskNo longer taking part
- Encore Medical Research LLCHollywood, United StatesContact: Novo NordiskNo longer taking part
- Southwest Clinical TrialsHouston, United StatesContact: Novo NordiskNo longer taking part
- Victorium Clinical ResearchHouston, United StatesContact: Novo NordiskNo longer taking part
- University of Florida CardiologyJacksonville, United StatesContact: Novo NordiskNo longer taking part
- Medical Colleagues-Texas LLPKaty, United StatesContact: Novo NordiskNo longer taking part
- Holston Medical Group.Kingsport, United StatesContact: Novo NordiskNo longer taking part
- Scripps Whittier Diabetes InstLa Jolla, United StatesContact: Novo NordiskNo longer taking part
- Diabetes & Endocrine Specialists - La MesaLa Mesa, United StatesContact: Novo NordiskNo longer taking part
- First Valley Med Grp LancasterLancaster, United StatesContact: Novo NordiskNo longer taking part
- Palm Research Center Inc-VegasLas Vegas, United StatesContact: Novo NordiskNo longer taking part
- Los Angeles Institute for Metabolic ResearchLos Angeles, United StatesContact: Novo NordiskNo longer taking part
- Solaris Clinical ResearchMeridian, United StatesContact: Novo NordiskNo longer taking part
- GTL Med & Res GroupMiami, United StatesContact: Novo NordiskNo longer taking part
- My Preferred ResearchMiami, United StatesContact: Novo NordiskNo longer taking part
- New Horizon Research CenterMiami, United StatesContact: Novo NordiskNo longer taking part
- Life Medical Research GroupMiami Gardens, United StatesContact: Novo NordiskNo longer taking part
- South Broward Research LLCMiramar, United StatesContact: Novo NordiskNo longer taking part
- Monroe Biomedical Research, LLCMonroe, United StatesContact: Novo NordiskNo longer taking part
- Adult Medicine of Lake County, Inc.Mt. Dora, United StatesContact: Novo NordiskNo longer taking part
- Southern NH Diabetes and Endo_NashuaNashua, United StatesContact: Novo NordiskNo longer taking part
- Clinical Research AssociatesNashville, United StatesContact: Novo NordiskNo longer taking part
- Valley Clinical Trials, Inc.Northridge, United StatesContact: Novo NordiskNo longer taking part
- West Orange EndocrinologyOcoee, United StatesContact: Novo NordiskNo longer taking part
- MedStar Health Research InstituteOlney, United StatesContact: Novo NordiskNo longer taking part
- Florida Institute for Clinical ResearchOrlando, United StatesContact: Novo NordiskNo longer taking part
- Desert Oasis Hlthcr Med GroupPalm Springs, United StatesContact: Novo NordiskNo longer taking part
- Rio Clinical Trials ArizonaPhoenix, United StatesContact: Novo NordiskNo longer taking part
- Rainier Clin Res Ctr IncRenton, United StatesContact: Novo NordiskNo longer taking part
- Endo And Metab ConsRockville, United StatesContact: Novo NordiskNo longer taking part
- NE Clin Res of San AntonioSan Antonio, United StatesContact: Novo NordiskNo longer taking part
- Pinnacle Clinical ResearchSan Antonio, United StatesContact: Novo NordiskNo longer taking part
- Linda Vista Health Care CtrSan Diego, United StatesContact: Novo NordiskNo longer taking part
- Diabetes & Endo Treatment SpecSandy City, United StatesContact: Novo NordiskNo longer taking part
- Southern Cal Clinical ResearchSanta Ana, United StatesContact: Novo NordiskNo longer taking part
- Consano Clinical Research, LLCShavano Park, United StatesContact: Novo NordiskNo longer taking part
- South Dakota Urban Indian HealthSioux Falls, United StatesContact: Novo NordiskNo longer taking part
- Spartanburg Medical ResearchSpartanburg, United StatesContact: Novo NordiskNo longer taking part
- Encompass Clinical Research_Spring ValleySpring Valley, United StatesContact: Novo NordiskNo longer taking part
- True Blue Clinical ResearchTampa, United StatesContact: Novo NordiskNo longer taking part
- Cotton O'Neil Diab & Endo CtrTopeka, United StatesContact: Novo NordiskNo longer taking part
- Diablo Clinical Research, Inc.Walnut Creek, United StatesContact: Novo NordiskNo longer taking part
- Chase Medical Research, LLCWaterbury, United StatesContact: Novo NordiskNo longer taking part
- Texas Valley Clinical ResearchWeslaco, United StatesContact: Novo NordiskNo longer taking part
- Southgate Medical Group, LLPWest Seneca, United StatesContact: Novo NordiskNo longer taking part
- Encore Medical Research of WestonWeston, United StatesContact: Novo NordiskNo longer taking part
- AccellacareWilmington, United StatesContact: Novo NordiskNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07931573EU 2026-525472-26-00
- Record updated
- 12 November 2026
- Original description
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will get one of the following: Zenagamtide (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator).Read full original descriptionShow less
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Higher Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both (AMBITION 3)
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will get one of the following: Zenagamtide (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator).
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent; Diagnosed with type 2 diabetes (T2D) above or equal to 180 days before screening; On stable daily dose(s) of metformin, sodium-glucose transport 2 (SGLT2) inhibitor, or both (at effective or maximum tolerated dose as judged by the investigator) prior to screening; Glycated haemoglobin (HbA1c) as determined by central laboratory at screening.
Exclusion: Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening; Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes is allowed as well as short term insulin treatment for a maximum of 14 consecutive days; Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening; Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation; Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening; Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method; Planned coronary, carotid or peripheral artery revascularisation.